Table 2.

Treatment-related adverse events for the immunotherapies in AML

Drug	Major toxicities
Talacotuzumab (CSL362)	Myelosuppression
Evaporcept (ALX148)	Urticaria, neutropenia, abdominal disconfort
Cusatuzumab	Neutropenia, Lung infection
Lintuzumab	Myelosuppression
Daratumumab, Isatuximab	Infusion site reaction, edema, neutropenia
Gemtuzumab Ozogamicin	Veno-occlusive disease, Hepatotoxicity
Gilteritinib	Ventricular arrythmia, myelosuppression
Vadastuximab talirine	Venous Thrombosis, myelosuppression
Immune Checkpoint Inhibitors	Immune-related adverse events (gastrointestinal, endocrine, dermatologic, neurotoxicity and pulmonary toxicity)
Chimeric antigen receptor T-cell therapies	CRS, ICANS